DOCSLIB.ORG

Increases in Biomarkers of Hyperglycemia with Age in The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Increases in Biomarkers of Hyperglycemia with Age in The e96 Diabetes Care Volume 40, August 2017 Increases in Biomarkers of Hyperglycemia Bethany Warren,1 Andreea M. Rawlings,1 With Age in the Atherosclerosis Risk in Alexandra K. Lee,1 Morgan Grams,1,2 Communities (ARIC) Study Josef Coresh,1 and Elizabeth Selvin1 Diabetes Care 2017;40:e96–e97 | https://doi.org/10.2337/dc17-0075 The American Diabetes Association’s Stan- glycated albumin, and some increase for the less consistent associations of age dards of Medical Care in Diabetesd2017 in fasting glucose, with modest impact of across the hyperglycemia biomarkers. Im- states that age should be “taken into con- adjustment for sex, race center (white, paired insulin secretion is common in sideration” when diagnosing diabetes Minneapolis, MN; black, Jackson, MS; white, older age. As HbA1c, fructosamine, and with HbA1c (1). Nonetheless, it is unclear Washington County, MD; black, Forsyth glycated albumin reflect postprandial how this recommendation might be im- County, NC; white, Forsyth County, NC; as glucose excursions in addition to fasting plemented. Population studies demon- defined by the ARIC study design), BMI, and concentrations, their stronger associa- 2 strate that HbA1c increases with age, BMI . At visit 5 among older adults tions with age as compared with fasting which some experts have suggested (21 years later), increases with age were glucose could reflectthatimpaired may be due to nonglycemic factors like less evident for fasting glucose and glucose tolerance is more common alterations in red cell turnover or hemo- HbA1c compared with fructosamine and than impaired fasting glucose in this globin glycation (2–4). However, prior glycated albumin. Associations of age population (5). studies lack concurrent comparisons with HbA1c, fructosamine, and glycated Similar to previous investigations, our across nonhemoglobin-related markers albumin at both visits persisted after fur- assessment is limited by its cross-sectional of hyperglycemia. We evaluated in- ther adjustment for fasting glucose. nature. Additionally, our analyses of older creases with age in fructosamine and gly- The magnitude of the association we adults could be subject to selection bias. cated albumindhemoglobin-independent observed between HbA1c and age, partic- Study strengths include the community- measures of hyperglycemiadin compar- ularly in middle age (0.11% [1.2 mmol/mol] based sample, broad age range, and mea- ison with HbA1c and fasting glucose in per 10 years of age), was similar to that in surements at different time points in the the community-based Atherosclerosis other studies (2–4). Prior investigations life span. Risk in Communities (ARIC) study. adjusted for glucose to account for glyce- In conclusion, we observed higher HbA1c We conducted serial cross-sectional anal- mia and attributed associations to non- at older ages but also saw comparable yses at visit 2 (1990–1992; n 5 11,632) and glycemic hemoglobin-related factors. associations for other (nonhemoglobin- visit 5 (2011–2013; n 5 3,876), excluding However, although HbA1c and fasting related) biomarkers of hyperglycemia. individuals with diagnosed diabetes. We glucose are highly related, they represent Our results provide some evidence that performed adjusted linear regression of different glycemic constructs. We ob- the age associations with HbA1c, fasting z scores of each biomarker (standardized served increases in HbA1c, fructosamine, glucose, fructosamine, and glycated albu- OBSERVATIONS to visit 2) on age to allow head-to-head and glycated albumin independent of min may reflect increases in the preva- – comparisons of the associations. fasting glucose, suggesting that increases lence of hyperglycemia in aging. Age was significantly correlated with all may be primarily glycemic or that puta- biomarkers of hyperglycemia at visit tive nonglycemic factors may influence e-LETTERS Ackowledgments. The authors thank the staff 2 (Fig. 1). In middle age (visit 2), we ob- nonhemoglobin biomarkers. and participants of the ARIC study for their served increases in HbA1c with age, com- The heterogeneity of dysglycemia across important contributions. Reagents for the gly- parable increases in fructosamine and the life span may offer some explanation cated albumin assays were donated by the 1Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 2Johns Hopkins University School of Medicine, Baltimore, MD Corresponding author: Elizabeth Selvin, [email protected]. Received 12 January 2017 and accepted 22 April 2017. © 2017 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. care.diabetesjournals.org Warren and Associates e97 Figure 1—Scatterplots with linear predictions, Pearson correlation coefficients, and unadjusted b coefficients (95% CIs) from linear regressions of z scores of markers of hyperglycemia (standardized to visit 2) on age (visit 2: 1990–1992 and visit 5: 2011–2013). HbA1c (A), fasting glucose (B), fructosamine (C), and glycated albumin (D). Black circles, visit 2 biomarker values; white line, visit 2 linear prediction; white circles, visit 5 biomarker values; black line, visit 5 linear prediction. *P , 0.05, **P , 0.001. Asahi Kasai Pharma Corporation. Reagents for Duality of Interest. No potential conflicts of evidence from the Framingham Offspring Study thefructosamineassaysweredonatedbyRoche interest relevant to this article were reported. and the National Health andNutritionExamination Diagnostics. Author Contributions. B.W. and E.S. designed Survey 2001–2004. Diabetes Care 2008;31:1991– Funding. ARIC is carried out as a collaborative the study, researched the data, and wrote the 1996 study supported by National Heart, Lung, and manuscript. A.M.R., A.K.L., M.G., and J.C. all pro- 3. Dubowitz N, Xue W, Long Q, et al. Aging is Blood Institute contracts HHSN268201100005C, vided meaningful contributions to the revision of associated with increased HbA1c levels, indepen- HHSN268201100006C, HHSN268201100007C, the manuscript. E.S. is the guarantor of this work dently of glucose levels and insulin resistance, and HHSN268201100008C, HHSN268201100009C, and, as such, had full access to all the data in the also with decreased HbA1c diagnostic specificity. HHSN268201100010C, HHSN268201100011C, study and takes responsibility for the integrity of Diabet Med 2014;31:927–935 and HHSN268201100012C. B.W., A.M.R., and thedataandtheaccuracyofthedataanalysis. 4. Ravikumar P, Bhansali A, Walia R, A.K.L. were supported by National Institutes of Shanmugasundar G, Ravikiran M. Alterations in Health National Heart, Lung, and Blood Institute References HbA1c with advancing age in subjects with normal grant T32HL007024. This research was sup- 1. American Diabetes Association. Standards of glucose tolerance: Chandigarh Urban Diabetes ported by National Institutes of Health National Medical Care in Diabetesd2017. Diabetes Care Study (CUDS). Diabet Med 2011;28:590–594 Institute of Diabetes and Digestive and Kidney 2017;40(Suppl. 1):S1–S135 5. Kalyani RR, Egan JM. Diabetes and altered Diseases grant R01DK089174, and E.S. was also 2. Pani LN, Korenda L, Meigs JB, et al. Effect of glucose metabolism with aging. Endocrinol Metab supported by K24DK106414. aging on A1C levels in persons without diabetes: Clin North Am 2013;42:333–347.
Load more

Recommended publications
  • Diabetes Control in Thyroid Disease
    In Brief Thyroid disease is commonly found in most types of diabetes. This article defines the prevalence of thyroid disease in diabetes and elucidates through case studies the assessment, diagnosis, and clinical management of thyroid disease in diabetes. Diabetes Control in Thyroid Disease Thyroid disease is a pathological state abnormality. Several studies, including that can adversely affect diabetes con- the Colorado study, have documented trol and has the potential to negative- a higher prevalence of thyroid disease Jennal L. Johnson, MS, RNC, FNP, ly affect patient outcomes. Thyroid in women, with prevalence rates rang- BC-ADM, CDE disease is found commonly in most ing from 4 to 21%, whereas the rate in forms of diabetes and is associated men ranges from 2.8 to 16%.1 with advanced age, particularly in Thyroid disease increases with age. In type 2 diabetes and underlying the Colorado study, the 18-year-olds autoimmune disease in type 1 dia- had a prevalence rate of 3.5% com- betes. This article defines the preva- pared with a rate of 18.5% for those lence of thyroid disease in diabetes, ≥ 65 years of age. discusses normal physiology and The prevalence of thyroid disease in screening recommendations for thy- diabetes has been estimated at 10.8%,2 roid disease, and elucidates through with the majority of cases occurring as case studies the assessment, diagnosis, hypothyroidism (~ 30%) and subclini- and clinical management of thyroid cal hypothyroidism (~ 50%).2 Hyper- disease and its impact on diabetes. thyroidism accounts for 12%, and postpartum thyroiditis accounts for Thyroid Disease Prevalence 11%.2 Of the female patients with The prevalence of thyroid disease in type 1 diabetes, 30% have thyroid dis- the general population is estimated to ease, with a rate of postpartum thy- be 6.6%, with hypothyroidism the roid disease three times that of the most common malady.1 Participants normal population.
    [Show full text]
  • CANINE INSULINOMA: DIAGNOSIS, TREATMENT, & STAGING Eliza Reiss Grant, DVM, and Kristine E
    Peer Reviewed PRACTICAL ONCOLOGY CANINE INSULINOMA: DIAGNOSIS, TREATMENT, & STAGING Eliza Reiss Grant, DVM, and Kristine E. Burgess, DVM, Diplomate ACVIM (Oncology) Tufts University An insulinoma is a malignant pancreatic tumor that DIAGNOSIS inappropriately secretes excessive insulin, resulting in Aside from a histologic confirmation of insulinoma, profound hypoglycemia.1 no currently available diagnostic test provides a de- Pancreatic tumors are classified as: finitive diagnosis of insulinoma. Existing techniques • Exocrine, which includes adenocarcinomas of may help increase suspicion for an insulin-secreting ductular or acinar origin tumor but, with most diagnostic testing, it is im- • Endocrine, which arise from the islets of perative to interpret all results in the context of the Langerhans. coexisting clinical signs. Insulinomas are functional neuroendocrine tumors that originate in the beta cells of the islets Differential Diagnosis of Langerhans.1 A complete work-up, including careful patient history, physical examination, bloodwork, and PRESENTATION diagnostic imaging tests, should be performed to Signalment rule out other causes of hypoglycemia, such as Any breed of dog can be affected, but large sepsis, hepatic failure, adrenal cortical insufficiency, breeds tend to be overrepresented.1 While, in toxin ingestion, and other forms of neoplasia. humans, insulinomas affect females far more frequently than males, there is no apparent sex Laboratory Tests predilection in dogs.1-3 Dogs also commonly Blood Glucose present with a malignant variant, while humans A simple fasting blood glucose level of less than often have a benign adenoma (80%).1 Insulino- 40 mg/dL can suggest hyperinsulinemia, although ma is rare in cats.4 careful monitoring of a fasted dog with suspected insulinoma is strongly recommended due to high Clinical Signs risk for seizure activity.
    [Show full text]
  • Bilirubin As a New Biomarker of Diabetes and Its Microvascular
    Analytica & l B y i tr o s c i h m e m e h i Biochemistry & s c t Nishimura, et al., Biochem Anal Biochem 2016, 5:1 o r i y B DOI: 10.4172/2161-1009.1000245 ISSN: 2161-1009 Analytical Biochemistry Commentary Open Access Bilirubin as a New Biomarker of Diabetes and its Microvascular Complications Takeshi Nishimura*, Masami Tanaka, Risa Sekioka and Hiroshi Itoh Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan *Corresponding author: Takeshi Nishimura, Department of Internal Medicine, School of Medicine, Keio University 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan, Tel: 81-3-5363-3797; Fax: 81-3-3359-2745; E-mail: [email protected] Rec date: Feb 06, 2016; Acc date: Feb 12, 2016; Pub date: Feb 15, 2016 Copyright: © 2016 Nishimura T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Commentary elucidate the pathophysiological role of bilirubin in type 1 DM, our results should be verified in large-scale, prospective studies. Hyperglycemia is the hallmark of diabetes mellitus [DM]; it activates certain biochemical pathways leading to micro- and macrovascular complications in diabetic patients [1]. Moreover, References hyperglycemia generates oxidative stress and causes free radical- 1. Takayanagi R, Inoguchi T, Ohnaka K (2011) Clinical and experimental mediated lipid peroxidation [2,3]. In turn, the oxidative stress causes evidence for oxidative stress as an exacerbating factor of diabetes mellitus.
    [Show full text]
  • Comparative Evaluation of Fructosamine and Hba1c As a Marker of Glycemic Control in Type 2 Diabetes: a Hospital Based Study
    International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Comparative Evaluation of Fructosamine and HbA1c as a Marker of Glycemic Control in Type 2 Diabetes: A Hospital Based Study Dr. Jyoti Goyal1, Dr. Nibhriti Das2, Dr. Navin Kumar3, Ms. Seema Raghav4, Dr. Paramjeet Singh Bhatia5, Dr. Karunesh Prasad Singh6, Dr. Sabari Das7 1DNB, Department of Internal Medicine, Nayati Healthcare and Research Centre, Mathura, India- 281003, 2Ex-Director of Laboratory services and Additional Dean Research and Academics, Nayati Healthcare and Research Centre, Mathura, India- 281003, 3Ph.D, Biostatistitian, Department of Biostatistics, Nayati Healthcare and Research Centre, Mathura, India-281003. 4M.Sc., Certified Diabetes Educator, Department of Internal Medicine, Nayati Healthcare and Research Centre, Mathura, India-281003. 5MD, Department of Internal Medicine, Nayati Healthcare and Research Centre, Mathura, India-281003. 6MD Physician, Department of Internal Medicine, Nayati Healthcare and Research Centre, Mathura, India-281003. 7Department of Laboratory Medicine, Nayati Healthcare and Research Centre, Mathura, India- 281003, Corresponding Author: Dr. Jyoti Goyal ABSTRACT Introduction: Management of type 2 diabetes revolves around achievement of target glycemic control with the help of antidiabetic drugs or insulin. There are various markers for measurement of glyceamic control like HbA1c, Mean Blood Glucose and fructosamine levels. Though HbA1c is a well validated standard method for assessment of glycemic control but it has also got certain limitations. Fructosamine, a less explored method may be used as an alternative marker for an assessment of glycemic control in cases where HbA1c is unreliable or unavailable. The objective of this study is to compare the fructosamine levels with HbA1c in assessment of glycemic control in type 2 diabetics so as to assess the utility of fructosamine as an alternative marker for evaluation of glucose control.
    [Show full text]
  • SIRS Is Valid in Discriminating Between Severe and Moderate Diabetic Foot Infections
    Pathophysiology/Complications ORIGINAL ARTICLE SIRS Is Valid in Discriminating Between Severe and Moderate Diabetic Foot Infections 1 2 DANE K. WUKICH, MD KATHERINE MARIE RASPOVIC, DPM best of our knowledge, the use of SIRS 2 3 KIMBERLEE B. HOBIZAL, DPM BEDDA L. ROSARIO, PHD has not yet been validated as a method of discriminating between moderate and severe DFI. OBJECTIVEdThis retrospective, single-center study was designed to distinguish severe di- The aim of this study was to classify abetic foot infection (DFI) from moderate DFI based on the presence or absence of systemic fl infectionseverityinagroupofhospital- in ammatory response syndrome (SIRS). ized diabetic patients based on the pres- RESEARCH DESIGN AND METHODSdThe database of a single academic foot and ence or absence of SIRS. The reason for ankle program was reviewed and 119 patients were identified. Severe DFI was defined as local hospitalization in this group of patients infection associated with manifestation of two or more objective findings of systemic toxicity was their DFI. Our hypotheses are that using SIRS criteria. patients with DFI who manifest SIRS (i.e., severe infection) will have longer hospital RESULTSdPatients with severe DFI experienced a 2.55-fold higher risk of any amputation – – stays and higher rates of major amputa- (95% CI 1.21 5.36) and a 7.12-fold higher risk of major amputation (1.83 41.05) than patients tion than patients who don’tmanifest with moderate DFI. The risk of minor amputations was not significantly different between the two groups (odds ratio 1.02 [95% CI 0.51–2.28]). The odds of having a severe DFI was 7.82 SIRS (i.e., moderate infection).
    [Show full text]
  • Diabetes - High Blood Sugar After Hours Telephone Triage Protocols | Adult | 2019
    Diabetes - High Blood Sugar After Hours Telephone Triage Protocols | Adult | 2019 DEFINITION ⦁ Patient with known diabetes mellitus ⦁ Has a high blood sugar (hyperglycemia), defined as a blood glucose > 200 mg/dL (11 mmol/L) ⦁ Has symptoms of high blood sugar ⦁ Has questions regarding high blood sugar SYMPTOMS of High Blood Sugar (Hyperglycemia) include: ⦁ Mild hyperglycemia: Most often patient will have no symptoms. ⦁ Moderate hyperglycemia: polyuria, polydipsia, fatigue, blurred vision. ⦁ Severe hyperglycemia: confusion and coma. ⦁ Diabetic ketoacidosis (DKA): fruity odor on breath, vomiting, rapid breathing, weakness, confusion, and coma. INITIAL ASSESSMENT QUESTIONS 1. BLOOD GLUCOSE: "What is your blood glucose level?" 2. ONSET: "When did you check the blood glucose?" 3. USUAL RANGE: "What is your glucose level usually?" (e.g., usual fasting morning value, usual evening value) 4. KETONES: "Do you check for ketones (urine or blood test strips)?" If yes, ask: "What does the test show now?" 5. TYPE 1 or 2: "Do you know what type of diabetes you have?" (e.g., Type 1, Type 2, Gestational; doesn't know) 6. INSULIN: "Do you take insulin?" "What type of insulin(s) do you use? What is the mode of delivery? (syringe, pen (e.g., injection or pump) 7. DIABETES PILLS: "Do you take any pills for your diabetes?" If yes, ask: "Have you missed taking any pills recently?" 8. OTHER SYMPTOMS: "Do you have any symptoms?" (e.g., fever, frequent urination, difficulty breathing, dizziness, weakness, vomiting) 9. PREGNANCY: "Is there any chance you are pregnant?"
    [Show full text]
  • Correlation Between Glycated Hemoglobin and Venous Blood Sugar in Diabetic Patients Monitored in Abidjan
    Vol. 14(4), pp. 135-141, October-December 2020 DOI: 10.5897/AJBR2020.1102 Article Number: CD65C6E65033 ISSN 1996-0778 Copyright © 2020 Author(s) retain the copyright of this article African Journal of Biochemistry Research http://www.academicjournals.org/AJBR Full Length Research Paper Correlation between glycated hemoglobin and venous blood sugar in diabetic patients monitored in Abidjan MONDE Aké Absalome1*, CAMARA-CISSE Massara2, KOFFI Konan Gervais2, DIALLO Issiagha3, AKE AKE Alexandre4, YAPO-AKE Bénédicte4, ECRABEY Yann Christian3, KOUAKOU Francisk3, BENE YAO Roger Espérance4 and TIAHOU Georges5 1Félix HOUPHOUËT-BOIGNY University, Cocody, Abidjan, Côte d’Ivoire. 2Biochemistry Laboratory, Abidjan Medical School, Félix HOUPHOUËT BOIGNY University, Côte D'ivoire. 3Biochemistry Laboratory, University Hospital Center of Treichville, Côte D'ivoire. 4Laboratory of Medical Biochemistry, Faculty of Medical Sciences, Félix HOUPHOUËT-BOIGNY University, Côte D'ivoire. 5Laboratory of Medical Biochemistry, Faculty of Medical Sciences, Alassane OUATTARA University, Bouaké, Côte D'ivoire. Received 23 August, 2020; Accepted 2 October, 2020 The aim of this study was to determine the correlation between glycated hemoglobin and blood sugar levels in diabetic subjects carried out in Abidjan. This cross-sectional study included 100 patients with diabetes monitored, for three months, for whom glycated blood glucose and hemoglobin were performed, this after informed consent of the patients. Pearson and Spearman correlation tests were used, at the 5% threshold. The patients with normal HbA1C and normal blood glucose accounted for 55.34 and 32%, respectively. A sedentary lifestyle and body mass index > 25 kg/m² were associated with a significant increase in the risk of increased blood glucose and HbA1C.
    [Show full text]
  • Glycation of Fetal Hemoglobin Reflects Hyperglycemia Exposure
    2830 Diabetes Care Volume 37, October 2014 Felix O. Dupont,1 Marie-France Hivert,1,2,3 Glycation of Fetal Hemoglobin Catherine Allard,1 Julie Menard,´ 1 Patrice Perron,1,2 Luigi Bouchard,1,4,5 Reflects Hyperglycemia Exposure Julie Robitaille,6 Jean-Charles Pasquier,1,7 Christiane Auray-Blais,1,8 and In Utero Jean-Luc Ardilouze1,2 Diabetes Care 2014;37:2830–2833 | DOI: 10.2337/dc14-0549 OBJECTIVE The lifetime risk of metabolic diseases in offspring of women with gestational diabetes mellitus (GDM) depends, at least in part, on the impact of glycemic fetal programming. To quantify this impact, we have developed and validated a unique mass spectrometry method to measure the percentage of glycated hemoglobin in cord blood. RESEARCH DESIGN AND METHODS This case-control study includes 37 GDM women and 30 pregnant women with normal glucose tolerance (NGT). RESULTS Glycation of the a-chain (Gla) was higher in neonates from GDM (2.32 vs. 2.20%, P < 0.01). Gla strongly correlated with maternal A1C measured at delivery in the r P < r P < overall cohort ( =0.67, 0.0001) as well as in each group (GDM: = 0.66, 1 r P Centre de Recherche du Centre Hospitalier Uni- 0.0001; NGT: = 0.50, = 0.01). versitaire de Sherbrooke, Sherbrooke, QC, Canada 2Endocrine Division, Universite´ de Sherbrooke, CONCLUSIONS Sherbrooke, QC, Canada Thus, Gla may reflect hyperglycemic exposure during the last weeks of fetal de- 3Harvard Pilgrim Health Care Institute, Depart- velopment. Future studies will confirm Gla is a predictive biomarker of prenatally ment of Population Medicine, Harvard Medical School, Boston, MA programmed lifetime metabolic health and disease.
    [Show full text]
  • Glucose Metabolism Before and After Radioiodine Therapy of a Patient with Graves' Disease: Assessment by Continuous Glucose Monitoring
    BIOMEDICAL REPORTS 7: 183-187, 2017 Glucose metabolism before and after radioiodine therapy of a patient with Graves' disease: Assessment by continuous glucose monitoring YUN HU, GU GAO, RENG-NA YAN, FENG-FEI LI, XIAO-FEI SU and JIAN-HUA MA Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210012, P.R. China Received March 17, 2017; Accepted June 7, 2017 DOI: 10.3892/br.2017.932 Abstract. Hyperthyroidism causes impaired glucose toler- as well as a diagnostic test for diabetes mellitus. However, ance, insulin resistance (IR) and insulin secretion. However, previous studies identified that HbA1c is not a reliable diag- the glucose variability affected by thyroid dysfunction remains nostic test for diabetes in the presence of hyperthyroidism or unclear. Glucose variability was assessed by continuous hypothyroidism (9,10). glucose monitoring (CGM) in a non-diabetic patient with The prevalent use of continuous glucose monitoring Graves' disease (GD), to the best of our knowledge, for the (CGM) has provided details on glycemic variation that were first time. A 28‑year‑old man with GD, who had been taking otherwise not possible with HbA1c or self-monitoring of methimazole for 4 years, was treated with radioiodine on blood glucose (SMBG). Torimoto et al (11) reported the use August 17th 2016. Although the patient exhibited normal of CGM in a patient with Graves' disease (GD) complicated glycated hemoglobin (HbA1c; 5.3%) and blood glucose values by diabetes mellitus. The authors demonstrated that hyper- during the oral glucose tolerance test (OGTT; fasting and thyroidism induces elevation of postprandial blood glucose 120 min blood glucose were 5.38 and 6.39 mmol/l, respec- (PBG) and fasting blood glucose (FBG) levels due to the dawn tively) before radioiodine therapy, CGM exhibited high 24 h phenomenon, and that glycemic variation is alleviated with mean glucose and nocturnal hyperglycemia.
    [Show full text]
  • Intracellular Calcium Leak Lowers Glucose Storage in Human Muscle
    RESEARCH ARTICLE Intracellular calcium leak lowers glucose storage in human muscle, promoting hyperglycemia and diabetes Eshwar R Tammineni1, Natalia Kraeva2,3, Lourdes Figueroa1, Carlo Manno1, Carlos A Ibarra2,3, Amira Klip4, Sheila Riazi2,3, Eduardo Rios1* 1Department of Physiology and Biophysics, Rush University Medical Center, Chicago, United States; 2Malignant Hyperthermia Investigation Unit (MHIU) of the University Health Network (Canada), Toronto, Canada; 3Department of Anaesthesia & Pain Management, Toronto General Hospital, UHN, University of Toronto, Toronto, Canada; 4Cell Biology Program, The Hospital for Sick Children, Toronto, Canada Abstract Most glucose is processed in muscle, for energy or glycogen stores. Malignant 2+ Hyperthermia Susceptibility (MHS) exemplifies muscle conditions that increase [Ca ]cytosol. 42% of MHS patients have hyperglycemia. We show that phosphorylated glycogen phosphorylase (GPa), glycogen synthase (GSa) – respectively activated and inactivated by phosphorylation – and their Ca2+-dependent kinase (PhK), are elevated in microsomal extracts from MHS patients’ muscle. 2+ Glycogen and glucose transporter GLUT4 are decreased. [Ca ]cytosol, increased to MHS levels, promoted GP phosphorylation. Imaging at ~100 nm resolution located GPa at sarcoplasmic reticulum (SR) junctional cisternae, and apo-GP at Z disk. MHS muscle therefore has a wide-ranging 2+ alteration in glucose metabolism: high [Ca ]cytosol activates PhK, which inhibits GS, activates GP and moves it toward the SR, favoring glycogenolysis. The alterations probably cause these patients’ hyperglycemia. For basic studies, MHS emerges as a variable stressor, which forces glucose pathways from the normal to the diseased range, thereby exposing novel metabolic links. *For correspondence: [email protected] Competing interests: The Introduction authors declare that no Skeletal muscle is the major processing site for dietary glucose, consuming it at a high rate during competing interests exist.
    [Show full text]
  • Assessing Blood Glucose Regulation
    Functional Medicine University’s Functional Diagnostic Medicine Training Program Mod 4 * FDMT533B Primary and Advanced Testing: Assessing Blood Glucose Regulation By Wayne L. Sodano, D.C., D.A.B.C.I., & Ron Grisanti, D.C., D.A.B.C.O., M.S. http://www.FunctionalMedicineUniversity.com Limits of Liability & Disclaimer of Warranty We have designed this book to provide information in regard to the subject matter covered. It is made available with the understanding that the authors are not liable for the misconceptions or misuse of information provided. The purpose of this book is to educate. It is not meant to be a comprehensive source for the topic covered, and is not intended as a substitute for medical diagnosis or treatment, or intended as a substitute for medical counseling. Information contained in this book should not be construed as a claim or representation that any treatment, process or interpretation mentioned constitutes a cure, palliative, or ameliorative. The information covered is intended to supplement the practitioner’s knowledge of their patient. It should be considered as adjunctive and support to other diagnostic medical procedures. This material contains elements protected under International and Federal Copyright laws and treaties. Any unauthorized reprint or use of this material is prohibited. Functional Medicine University; Functional Diagnostic Medicine Training Program/Insider’s Guide Module 4: FDMT 533B: Primary and Advanced Testing: Assessing Blood Glucose Regulation Copyright © 2010 Functional Medicine University, All Rights Reserved Functional Medicine University’s Functional Diagnostic Medicine Training Program Module 4: FDMT 533B: Primary and Advanced Testing: Assessing Blood Glucose Regulation By Wayne L.
    [Show full text]
  • Hyperglycemia – Prediabetes
    North Dakota Family Planning Program Clinical Protocol Manual Health Maintenance – HM 8 Hyperglycemia – Prediabetes DEFINITION Hyperglycemia is an excess of glucose in the blood. Prediabetes is a condition when blood glucose levels are higher than normal but not yet high enough to be diagnosed as diabetes. (Prediabetes is also known as Impaired Glucose Tolerance (IGT) or Impaired Fasting Glucose (IFG) depending on which test was used to detect it. IGT uses the oral glucose tolerance test and IFG uses the fasting plasma glucose test.) SUBJECTIVE May include: 1. No symptoms 2. Family history of diabetes 3. Weight changes 4. Fatigue, blurred vision, recurrent vulvovaginal candidiasis 5. History of gestational diabetes or birth weight of newborn 9 lbs. or greater 6. Polydipsia, polyphagia, or polyuria 7. 20% over ideal body weight; sedentary lifestyle 8. Decreased wound healing 9. Race (higher incidence of diabetes among American Indian, Hispanic, and African American population) 10. History of hypertension 11. History of decreased HDL and increased triglycerides 12. History of Polycystic Ovarian Syndrome or Metabolic Syndrome 13. History of antipsychotic medication therapy OBJECTIVE May include: 1. Blood pressure 2. Height and weight 3. Complete physical exam. Acanthosis Nigricans may be noted in axillae, groin, and/or neck LABORATORY May refer for: 1. Hyperglycemia a. lab of choice may include one or more of the following: i. Fasting plasma glucose (FPG) a) Prediabetes: FPG between 100 mg/dl to 125 mg/dl b) Diabetes: FPG is > 126 mg/dl ii. Oral Glucose Tolerance Test (OGTT) a) Prediabetes: OGTT 140mg/dl to 199 mg/dl b) Diabetes: OGTT 200mg/dl or higher iii.
    [Show full text]